BRPI0506719A - composto, composição farmacêutica, e, uso de um composto - Google Patents

composto, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0506719A
BRPI0506719A BRPI0506719-7A BRPI0506719A BRPI0506719A BR PI0506719 A BRPI0506719 A BR PI0506719A BR PI0506719 A BRPI0506719 A BR PI0506719A BR PI0506719 A BRPI0506719 A BR PI0506719A
Authority
BR
Brazil
Prior art keywords
compound
halo
alkyl
pharmaceutical composition
sym
Prior art date
Application number
BRPI0506719-7A
Other languages
English (en)
Inventor
Magnus Nilsson
Xiao-Xiong Zhou
Lourdes Oden
Bjorn Classon
Rolf Noren
Urszula Grabowska
Philip Jackson
Philip Fallon
Andrew Carr
Marck Liley
Matt Tozer
Tony Johnson
Victor Diaz
Laia Crespo
Jussi Kangasmetsa
Thierry Bonnaud
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0400022A external-priority patent/SE0400022D0/xx
Priority claimed from SE0401332A external-priority patent/SE0401332D0/xx
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of BRPI0506719A publication Critical patent/BRPI0506719A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTO,COMPOSIçãO FARMACêUTICA,E,USO DE UM COMPOSTO Um composto de fórmula (II) em que um de R¬ 1e R¬ 2é halo e o outro é H ou halo; R¬ 3 é alquila de cadeia reta ou ramificada C~ 1-C~ 4, opcionalmente fluorada; R¬ 4é H; ou R¬ 3, junto com R¬ 4 e o carbono da cadeia principal contíguo define : uma espiro-C~ 5-C~ 7 cicloalquila, opcionalmente substituída com 1 a 3 substituintes selecionados de halo, hidroxila,C~ 1-C~ 4 alquila ou C~ 1-C~4 haloalquila; ou, opcionalmente,com ligação em ponte com um grupo metileno; ou um heterociclo saturado C~ 4-C~ 6, tendo um hetero átomo selecionado de O,NRa,SS(=O)~ 2; em que Ra é H,C~ 1-C~ 4 alquila ou CH~ 3C(=O); R¬ 5 é independentemente selecionado de H ou metila; E é -C(=O)-,-S(-O)<sym>,-NR¬ 5S(=O)<sym>-,-NR¬ 5C(=O)- -OC(=O)-,R¬ 6 é carbociclo ou heterociclo , monocíclico ou bicíclico, opcionalmente substituído,estável; m é independentemente 0, 1 ou 2; são inibidores da catepsina K e úteis no tratamento ou profilaxia da osteoporose.
BRPI0506719-7A 2004-01-08 2005-01-06 composto, composição farmacêutica, e, uso de um composto BRPI0506719A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0400022A SE0400022D0 (sv) 2004-01-08 2004-01-08 New compounds
SE0401332A SE0401332D0 (sv) 2004-05-26 2004-05-26 New compounds
PCT/GB2005/050003 WO2005066180A1 (en) 2004-01-08 2005-01-06 Cysteine protease inhibitors

Publications (1)

Publication Number Publication Date
BRPI0506719A true BRPI0506719A (pt) 2007-05-02

Family

ID=34752290

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506719-7A BRPI0506719A (pt) 2004-01-08 2005-01-06 composto, composição farmacêutica, e, uso de um composto

Country Status (12)

Country Link
US (2) US7915300B2 (pt)
EP (1) EP1701960B1 (pt)
JP (1) JP4787765B2 (pt)
AR (1) AR047373A1 (pt)
AT (1) ATE461200T1 (pt)
AU (1) AU2005203972B2 (pt)
BR (1) BRPI0506719A (pt)
CA (1) CA2552739A1 (pt)
DE (1) DE602005019971D1 (pt)
ES (1) ES2341869T3 (pt)
TW (1) TWI343384B (pt)
WO (1) WO2005066180A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005019971D1 (de) 2004-01-08 2010-04-29 Medivir Ab Inhibitoren von cysteinprotease
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
GB0513840D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0517279D0 (en) * 2005-08-23 2005-10-05 Amura Therapeutics Ltd Biologically active compounds
CA2623327A1 (en) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
GB0611654D0 (en) * 2006-06-13 2006-07-19 Medivir Ab Compounds
GB0614053D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614052D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614046D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614037D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614073D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614044D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0618263D0 (en) * 2006-09-18 2006-10-25 Medivir Ab Compound
WO2008114054A1 (en) * 2007-03-19 2008-09-25 Medivir Ab Protease inhibitors
KR20100023948A (ko) 2007-06-08 2010-03-04 닛뽕 케미파 가부시키가이샤 뇌동맥류의 치료 또는 예방약
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
ES2655466T3 (es) 2007-08-13 2018-02-20 Monsanto Technology Llc Composiciones y procedimientos de control de nematodos
JPWO2009054454A1 (ja) 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
JP5587790B2 (ja) * 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
GB0817424D0 (en) 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
US10087190B1 (en) * 2017-04-24 2018-10-02 Purdue Research Foundation Lactones
US10995803B2 (en) 2018-12-04 2021-05-04 Means Industries, Inc. Electromagnetic system for controlling the operating mode of a non friction coupling assembly and coupling and magnetic control assembly having same
WO2022147694A1 (en) * 2021-01-06 2022-07-14 Beijing Erai Therapeutics Co., Ltd. Aminoheteroaryl compounds and uses thereof
EP4613273A1 (en) 2024-03-06 2025-09-10 Vetbiolix Treatment of bone loss

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013079A1 (es) 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
EP1358183B1 (en) 2000-11-17 2006-04-12 Medivir Ab Cysteine protease inhibitors
PT1362052E (pt) 2001-01-17 2007-04-30 Amura Therapeutics Ltd Inibidores de cruzipaína e de outras proteases de cisteína
JP2003183161A (ja) * 2001-12-21 2003-07-03 Kitasato Inst:The 骨粗鬆症の予防治療剤
CA2548600A1 (en) 2003-12-12 2005-06-23 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US20080200975A1 (en) 2004-01-06 2008-08-21 Nicast Ltd. Vascular Prosthesis with Anastomotic Member
DE602005019971D1 (de) 2004-01-08 2010-04-29 Medivir Ab Inhibitoren von cysteinprotease
EP1706402A4 (en) 2004-01-08 2009-03-18 Merck Frosst Canada Ltd CATHEPSINCYSTEINPROTEASEHEMMER
GB0513839D0 (en) 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0614052D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
EP1701960B1 (en) 2010-03-17
CA2552739A1 (en) 2005-07-21
ES2341869T3 (es) 2010-06-29
HK1096956A1 (en) 2007-06-15
TWI343384B (en) 2011-06-11
US7915300B2 (en) 2011-03-29
US20080234260A1 (en) 2008-09-25
AU2005203972A1 (en) 2005-07-21
EP1701960A1 (en) 2006-09-20
JP2007517852A (ja) 2007-07-05
TW200536847A (en) 2005-11-16
DE602005019971D1 (de) 2010-04-29
ATE461200T1 (de) 2010-04-15
JP4787765B2 (ja) 2011-10-05
AU2005203972B2 (en) 2010-11-18
WO2005066180A9 (en) 2008-09-25
US20110112089A1 (en) 2011-05-12
AR047373A1 (es) 2006-01-18
WO2005066180A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
BRPI0514632A (pt) derivados de ftalazinona 4-heteroarilmetila substituìdos
BRPI0512916A (pt) derivado de tienopirazol tendo atividade inibidora de pde 7
CO6140059A2 (es) Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3)
BR0309534A (pt) Composto, composição farmacêutica, e, uso de um composto
AR057023A1 (es) Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
CO5261551A1 (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
BRPI0510623A (pt) compostos de derivados de prolina e morfolina
NO20082934L (no) Antivirale nukleotider
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
WO2008108386A1 (ja) 医薬組成物
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
EA200401381A1 (ru) 3-гетероарилзамещённые изоксазолины
AR047529A1 (es) Compuestos de quinolina sustituidos
BRPI0518068A (pt) composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
ECSP10010380A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BRPI0406500A (pt) processo farmacêutico e compostos preparados pelo mesmo
EA201070010A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
BR0212716A (pt) Inibidores de liberação extracelular de citocinas inflamatórias e composição farmacêutica
BR0316785A (pt) Derivados de 4-pirimidona-3-substituìdos
HRP20080538T3 (en) Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
BRPI9911178B8 (pt) derivados de 3-(2-oxo-[1,3&#39;]bipirrolidinil-3-ilidenometil)-cefems, bem como preparação farmacêutica e uso dos mesmos
ECSP045176A (es) Derivados de 5-(piridin-3-il)-1-azabiciclo[3.2.1]octano, su preparacion y su aplicación en terapeutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2205 DE 09/04/2013.